Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2022-02-10 Major Shareholding Noti…
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2022-02-10 English
SC 13D
Major Shareholding Notification
2022-01-20 English
DEF 14A
Proxy Solicitation & Information Statement
2022-01-05 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is soliciting shareholder votes for a Special General Meeting, specifically for the approval of the appointment of the CEO to Chairman of the Board. The text includes detailed voting instructions, meeting details, and proxy solicitation information. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is not an announcement of voting results, nor is it a full annual or quarterly report, nor a management or governance report. It is a proxy statement for a special meeting, thus classified as PSI.
2021-12-23 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content focuses on the departure of a chairman of the board and the appointment process of a new chairman, including approvals by the nominating committee and board. There is no financial data or detailed financial performance information. The primary subject is changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5348 characters, which is sufficient to contain substantive information about management changes rather than a brief announcement. Hence, the classification is MANG with high confidence.
2021-12-16 English
Director's Dealing 2021
Director's Dealing
2021-12-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.